Skip to content

Pulmonx Corporation LUNG Other accrued liabilities

Other accrued liabilities at other companies

Intuitive Surgical logo
Intuitive SurgicalISRG
Theravance Biopharma logo
Theravance BiopharmaTBPH
Viemed Healthcare, Inc. logo
Viemed Healthcare, Inc.VMD
LivaNova logo
LivaNovaLIVN

Other financials

Income statement

See full
Revenue$20.6M-8.7%
Gross profit$16.0M-1.8%
Operating income-$13.0M+11.0%
Net income-$13.7M+5.5%
EPS (diluted)-$0.33+8.3%

Balance sheet

See full
Cash & equivalents$61.0M-2.4%
Total debt$56.3M-1.2%
Total equity$45.8M-41.1%
Total assets$120.0M-20.4%

Cash flow

See full
Operating cash flow-$10.1M+23.6%
CapEx$9.0K-97.0%
Free cash flow-$10.1M+25.3%

Valuation

See full
Market cap$54.91M-43.7%
Enterprise value$50.17M-39.2%
P/S0.6×-0.5×

Profitability

See full
Gross margin75.5%+2.0pp
Operating margin-58.8%-5.8pp
Net margin-60.1%-4.4pp
FCF margin-33.2%-4.4pp

Returns & leverage

See full
Return on equity-86.2%+62.6pp
Debt / equity1.2×+0.5×
Current ratio4.9×-0.1×

Where this comes from

Reported directly by Pulmonx Corporation in its filing.

Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.

The official record: Pulmonx Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pulmonx Corporation's other accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pulmonx Corporation's other accrued liabilities?
Pulmonx Corporation (LUNG) reported other accrued liabilities of $349K in Q1 2026.
How has Pulmonx Corporation's other accrued liabilities changed year-over-year?
Pulmonx Corporation's other accrued liabilities decreased by 24.3% year-over-year, from $461K to $349K.
What is the long-term trend for Pulmonx Corporation's other accrued liabilities?
Over 5 years (2020 to 2025), Pulmonx Corporation's other accrued liabilities has grown at a 10.3% compound annual growth rate (CAGR), from $579K to $947K.